Yin Lijuan, Li Jinhua
Center of Oncology, Jiangsu Province Hospital, Nanjing, People's Republic of China.
Cancer Manag Res. 2020 Jul 14;12:5813-5818. doi: 10.2147/CMAR.S250410. eCollection 2020.
Central venous catheters (CVCs) have been demonstrated as a feasible method for chemotherapy delivery in colorectal cancer patients. The objective of our study was to explore the preference of colorectal cancer patients (89%) in our institution for port catheters (PCs) through comparing the costs and complications between peripherally inserted central venous catheters (PICCs) and PCs.
Overall, 777 colorectal cancer patients (89%) were eligible for central venous catheter (CVC) insertions from January 1, 2017, to January 1, 2019. We retrospectively compared the costs and complications following the introduction of PICCs and PCs in the infusion of intravenous chemotherapy agents in patients with colorectal cancer.
A total of 773 colorectal patients were enrolled. The total cost of PICC and PC was US $436.20 and US $976, respectively. The complication rate was higher in the PICC compared with the PC group (45% versus 4%, P <0.001). The late complication rate of the two groups was particularly pronounced (52% versus 7%, p < 0.001). The incidence rate of total complications, that were developed in patients, with and without hemostatic prophylaxis, was 0.7% versus 5.7% (p < 0.001).
Port devices are associated with higher costs but fewer complications, compared to PICC in patients with colorectal cancer.
中心静脉导管（CVC）已被证明是一种用于结直肠癌患者化疗给药的可行方法。我们研究的目的是通过比较经外周静脉穿刺中心静脉导管（PICC）和植入式静脉输液港（PC）的成本和并发症，探讨我们机构中结直肠癌患者（89%）对植入式静脉输液港的偏好。
总体而言，2017年1月1日至2019年1月1日期间，777例结直肠癌患者（89%）符合中心静脉导管插入条件。我们回顾性比较了在结直肠癌患者静脉化疗药物输注中引入PICC和植入式静脉输液港后的成本和并发症。
共纳入773例结直肠癌患者。PICC和植入式静脉输液港的总成本分别为436.20美元和976美元。PICC组的并发症发生率高于植入式静脉输液港组（45%对4%，P<0.001）。两组的晚期并发症发生率尤为明显（52%对7%，P<0.001）。在有和没有止血预防措施的患者中发生的总并发症发生率分别为0.7%和5.7%（P<0.001）。
与结直肠癌患者的PICC相比，植入式静脉输液港成本更高，但并发症更少。
